Safety Alerts & Recalls
What does this mean?
A report made to Strathclyde Pharmaceuticals Ltd that the incorrect strength (15mg) of Xarelto (Rivaroxaban) has been found in 20mg packs, has prompted them to issue a recall of one batch. If you, or somebody you know, uses takes Xarelto (Rivaroxaban) 20mg tablets, please compare the batch number against the ones above. If it matches, please then check if there are any tablets or blisters in the carton labelled as 15 mg. If so, please speak to your community pharmacist as soon as possible about obtaining a replacement pack. It is important that you do not stop taking your medication, unless instructed to by a healthcare professional.
If you or somebody you know have been dispensed Xarelto (rivaroxaban) 20 mg tablets in compliance aids (containers with all the medication for each day of the week) since 18 September 2017 inclusive, please return all your compliance aids to the pharmacy in order to be issued with replacements. If you have any questions or concerns about the contents of this alert, please discuss them with your pharmacist or doctor.
Strathclyde Pharmaceuticals Ltd recalls single batch of Xarelto 20mg film-coated tablets after reports of rogue blister strips of 15 mg tablets within packs of 20 mg tablets
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an alert advising the recall of one batch of Xarelto (Rivaroxaban) 20mg tablets. The affected batch number is BXHHDR1 with expiry date 09/2019, and it was first distributed on 18/09/2017. This follows reports to the manufacturers, Strathclyde Pharmaceuticals Ltd, of a rogue blister strip of 15 mg tablets being found within two packs of 20 mg tablets. As a result, they have decided to recall the entire batch.
Xarelto, which contains the medication Rivaroxaban, thins the blood and is used to prevent blood clots and lower the risk of stroke.
For more information and for a comprehensive list of batch numbers affected, please visit: more information here